Point of Care Diagnostic to Identify the Causative Agent of the Plague in Blood Samples

Status: Unknown
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Plague is a deadly but highly treatable disease caused by the bacterium Y. pestis. Due to the historical development of Y. pestis as a bioweapon by several nation states, it is listed by the US as a potential bioweapon that could be used against US warfighters. Although this bacterium is ecologically established worldwide, it mostly affects impoverished people who live in rural low-resource areas of Madagascar. Plague is acquired directly from bites of infected fleas but, if left untreated, it can progress to the highly lethal pneumonic form that can result in human to human transmission. With the dangers of pneumonic plague in the context of both natural outbreak and as a bioweapon used against warfighter, the goal of this study is to investigate a diagnostic test that is able to rapidly and locally diagnose this disease in low-resource settings. This study aims to evaluate a US-developed new LFI (Lateral Flow Immunoassay) assay intended for capillary blood (finger-prick) to diagnose humans infected with Y. pestis. The investigators will rigorously validate with assay on human populations from active plague sites and correlate the results with the results of paired clinical samples used in standard medical workup using existing diagnostics tests.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 75
Healthy Volunteers: f
View:

• Adults 18 to 75 years old (male and female): Able to receive and give verbal communication.

• Children 5 to 17 years old (vulnerable population): Parents or legal guardian must be available to give permission. Parents or legal guardian to consent for children (5-6 years).

• Suspected human plague case by local medical professional. Include at least one of the following: For bubonic plague: high fever, chills, and/or presence of painful bubo; For pneumonic plague: high fever, chills, cough for less than 5 days, bloody sputum, and/or chest pains; patients may be recruited from both plague surveillance program and non-plague surveillance programs.

• Active duty personnel and DoD beneficiaries that present to participating study sites with influenza-like-illness (fever, cough, sore throat).

• Age range \>=13 to 75 y.o.

• Able to receive/give consent (or assent if \<18 y.o.) 4, Presenting with influenza-like-illness (fever of 100.5 F or higher, cough and/or sore throat)

⁃ 5\. USN Special Categories: Minors/children (45CFR Subpt. D/DoDI 3216.02, Encl 3, Para 7d); Students; Active duty military personnel (3216.02, Encl.3 Para. 7.e); Economically disadvantaged persons (32CFR 219.11(b); Educationally disadvantaged persons (32CFR 219.11(b).

Locations
United States
California
US Naval Health Research Center
RECRUITING
San Diego
Other Locations
Madagascar
Institut Pasteur de Madagascar
RECRUITING
Antananarivo
Contact Information
Primary
David P Trudil
Davidt@nhdetect.com
410-499-7062
Backup
Gregory R Siragusa, Ph.D.
gsiragusa@nhdiag.com
262-309-5360
Time Frame
Start Date: 2020-10-19
Completion Date: 2023-01
Participants
Target number of participants: 500
Treatments
Malagasy Participants
Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
USN Health Research Center
USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
Related Therapeutic Areas
Sponsors
Collaborators: Institut Pasteur de Madagascar, Naval Health Research Center, Northern Arizona University, New Horizons Diagnostics Corporation
Leads: Brimrose Technology Corporation

This content was sourced from clinicaltrials.gov